Combination drug - PDFSEARCH.IO - Document Search Engine

Combination drug
Results: 675

#	Item
241	® HYZAAR[removed]LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS) Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2014-10-01 15:38:44 Organic chemistry Angiotensin II receptor antagonists Imidazoles Tetrazoles Combination drugs Losartan Hydrochlorothiazide/losartan Aliskiren Antihypertensive drug Chemistry Medicine Alcohols
242	BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA THERAPEUTIC PREFERRED AGENTS Add to Reading List Source URL: www.dhhr.wv.gov Language: English - Date: 2010-12-03 12:26:05 Morphinans Combination drugs Anti-acne preparations Ketones Alcohols Hydrochlorothiazide Oxycodone Clindamycin Codeine Chemistry Organic chemistry Pharmacology
243	The following is a list of the most commonly prescribed drugs. It represents an abbreviated version of the drug list (formulary) that is at the core of your prescription-drug benefit plan. The list is not all-inclusive a Add to Reading List Source URL: statehealthplan.state.nc.us Language: English - Date: 2014-10-14 15:36:23 Angiotensin II receptor antagonists Tetrazoles Alcohols Hypnotics Hydrochlorothiazide Valsartan Olmesartan Sulfonamide Antihypertensive drug Chemistry Organic chemistry Combination drugs
244	Vermont Board of Pharmacy Policy on Hydrocodone Combination Products as Schedule II Drugs As of October 6, 2014 any hydrocodone combination product will be a DEA Schedule II drug. Rule[removed]of the Administrative Rules o Add to Reading List Source URL: www.healthvermont.gov Language: English - Date: 2014-09-30 13:05:59 Pharmacology Morphinans Clinical pharmacology Medical prescription Patient safety Drug Enforcement Administration Hydrocodone Pharmacy Controlled Substances Act Chemistry Medicine Health
245	HYDROCODONE COMBINATION PRODUCTS: FACT SHEET On August 22, 2014, the DEA published a final rule rescheduling hydrocodone combination products (HCPs) to schedule II of the Controlled Substances Act. The final rule is avai Add to Reading List Source URL: www.llr.sc.gov Language: English - Date: 2014-10-02 09:46:19 Morphinans Pharmacology Drug Enforcement Administration Controlled Substances Act Hydrocodone Medical prescription Oxycodone Chemistry Organic chemistry Ketones
246	Vermont Board of Pharmacy Policy on Hydrocodone Combination Products as Schedule II Drugs As of October 6, 2014 any hydrocodone combination product will be a DEA Schedule II drug. Rule[removed]of the Administrative Rules o Add to Reading List Source URL: healthvermont.gov Language: English - Date: 2014-09-30 13:05:59 Pharmacology Morphinans Clinical pharmacology Medical prescription Patient safety Drug Enforcement Administration Hydrocodone Pharmacy Controlled Substances Act Chemistry Medicine Health
247	FDA Patient Safety News: Show #21, November 2003 Add to Reading List Source URL: www.fda.gov Language: English Medicine Pharmaceutical sciences GlaxoSmithKline Combination drugs Clinical research Fluticasone/salmeterol Salmeterol MedWatch Adverse event Food and Drug Administration Pharmaceutical industry Pharmacology
248	FDA Patient Safety News: Show #57, November 2006 Add to Reading List Source URL: www.fda.gov Language: English Purines Non-steroidal anti-inflammatory drugs Combination drugs Food and Drug Administration Mercaptopurine DPT vaccine Selective serotonin reuptake inhibitor Adverse effect Azathioprine Medicine Pharmacology Chemistry
249	The Commonwealth of Massachusetts DEVAL L. PATRICK GOVERNOR JOHN W. POLANOWICZ Add to Reading List Source URL: www.mass.gov Language: English - Date: 2014-10-06 13:35:07 Morphinans Ketones Analgesics Combination drugs Drug Enforcement Administration Hydrocodone Controlled Substances Act Medical prescription Pharmacy Chemistry Pharmacology Medicine
250	FDA Patient Safety News: Show #54, August 2006 Add to Reading List Source URL: www.fda.gov Language: English Vaccines Papillomavirus Merck Combination drugs Merck & Co. Gadolinium Food and Drug Administration Lisinopril Nephrogenic systemic fibrosis Chemistry Pharmacology Medicine